$IMVTImmunovant, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
  CEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
  biospace · 3h ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 7d ago
• Lilly’s latest China drug deal; Immunovant’s setback in lupus
  Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
  biopharma_dive · 10d ago
• Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
  After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high priority programs for the drug i…
  biospace · 11d ago
• Roivant reports Phase 2b lupus failure for an FcRn drug
  One of Roivant’s leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did not impr…
  endpoints · 11d ago
• Immunovant ends cutaneous lupus program after phase 2 flop
  Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
  fiercebiotech · 11d ago